ISSN:
1573-0646
Keywords:
methyl-glyoxal-bis-guanylhydrazone
;
MGBG
;
non-small cell carcinoma of the lung
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary One hundred and eight patients with non-small cell lung cancer were treated in a Phase II trial with MGBG at a dose of 600 mg/m2 i.v. weekly. Partial responses were noted in 3/43 patients with adenocarcinoma and 1/40 with squamous cell carcinoma. No responses were noted in 24 patients with large cell carcinoma. Overall, the drug was reasonably well-tolerated. At this dosage and schedule, MGBG has no substantial antitumor activity for patients with non-small cell lung cancer.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00180196
Permalink